SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione N-oxide (as per EP)
Synonym: erythromycin A 3″-N-oxide (EP) ; Erythromycin A N-oxide
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: C[C@@H]([C@@H]([C@H](C(O[C@@H]1CC)=O)C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@](O)(C[C@H](C([C@@H]([C@@H](O)[C@@]1(O)C)C)=O)C)C)O[C@@](O[C@H](C)C[C@@H]3[N+](C)([O-])C)([H])[C@@H]3O
Erythromycin EP Impurity H is chemically (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione N-oxide (as per EP). It is also known as erythromycin A 3″-N-oxide (EP) ; Erythromycin A N-oxide. Erythromycin EP Impurity H is supplied with detailed characterization data compliant with regulatory guideline. Erythromycin EP Impurity H can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Erythromycin.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Isolation and identification of a novel erythromycin-degrading fungus, Curvularia sp. RJJ-5, and its degradation pathway
By Ren, Jianjun; Deng, Liujie; Niu, Dongze; Wang, Zhenzhu; Fan, Bo; Taoli, Huhe; Li, Zhijie; Zhang, Jin; Li, Chunyu
From FEMS Microbiology Letters (2021), 368(1), fnaa215.
Development and validation of a stability indicating HPLC method for organic impurities of erythromycin stearate tablets
By Jeelani, Salika; Soukhova, Nadejda
From Journal of Pharmaceutical and Biomedical Analysis (2021), 195, 113858
Degradation and mineralization of erythromycin by heterogeneous photocatalysis using SnO2-doped TiO2 structured catalysts: Activity and stability
By Albornoz, L. L.; da Silva, S. W.; Bortolozzi, J. P.; Banus, E. D.; Brussino, P.; Ulla, M. A.; Bernardes, A. M.
From Chemosphere (2021), 268, 128858